We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Emergent BioSolutions has announced that it has successfully delivered more than 3 million doses of BioThrax, the only FDA-approved anthrax vaccine, to HHS for placement into the nation's strategic national stockpile.
Roche has announced that its oral cancer medicine Tarceva (erlotinib) has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use following a reexamination of the data supporting the use of Tarceva in metastatic pancreatic cancer.
Ranbaxy Laboratories has entered into a collaborative agreement with India's Department of Science & Technology in the area of new drug discovery research.
The President's Emergency Plan for AIDS Relief (PEPFAR) has been slow to allow the procurement of generic antiretroviral (ARV) drugs to treat HIV, according to a new report by the organization Center for Public Integrity.
Two children die every hour from easily preventable pneumococcal diseases in Latin America and the Caribbean, and there are more than 1.6 million cases of the illnesses that include pneumonia, meningitis and sepsis as well as severe ear infections, sinusitis and bronchitis, according to a United Nations-backed report.
Aid organization Oxfam has issued a statement criticizing three high-profile patent disputes that could have a devastating effect on poor people's access to affordable medicines.
The production line at an antiretroviral (ARV) drug manufacturing facility in the Democratic Republic of Congo (DRC) sits idle, while many people with HIV go without treatment, the UN Integrated Regional Information Networks (IRIN) reports.
U.S. drugmaker Gilead Sciences has announced an agreement under which the company will grant the rights to develop, manufacture and, if proven efficacious, distribute its antiretroviral tenofovir as a microbicide to prevent HIV infection.
A UK governmental commission has called for the establishment
of an open-access database of information for certain high-risk Phase I clinical trials, along with 21 other recommendations that are intended to prevent any repeat of the catastrophic Phase I clinical trial of the gene therapy TGN1412.